Bogaert M G
Clin Pharmacokinet. 1983 Sep-Oct;8(5):410-21. doi: 10.2165/00003088-198308050-00003.
Plasma concentrations of glyceryl trinitrate (nitroglycerin), isosorbide dinitrate and isosorbide 2- and 5-mononitrates in man have been measured after administration via different routes. Appropriate precautions have to be taken in the administration of these agents (to avoid loss during intravenous infusion), and in their sampling and assay. Pharmacokinetic calculations based on plasma concentrations should be viewed with caution, as the data on which these calculations are based are often very limited, and the very rapid disappearance of for example glyceryl trinitrate from plasma makes the choice of an appropriate kinetic model and exact calculations difficult. Glyceryl trinitrate disappears from plasma within a few minutes, and a high apparent volume of distribution and a very high systemic clearance are found. After oral administration, plasma concentrations are very low; with sublingual or cutaneous administration, higher plasma concentrations can be obtained, suggesting a high first-pass extraction after oral administration, but quantitative data on bioavailability are lacking. For isosorbide dinitrate the systemic clearance, although high, is lower than for glyceryl trinitrate; disappearance from the plasma is slower and plasma concentrations after different routes of administration are much higher. Here too, quantitative data on bioavailability are lacking. High plasma concentrations of isosorbide 2-mononitrate and isosorbide 5-mononitrate are found in plasma after administration of isosorbide dinitrate. These metabolites have a good bioavailability, and half-lives of around 2.5 hours for isosorbide 2-mononitrate and 5 hours for isosorbide 5-mononitrate. Only very limited data are available about the influence of disease states and interactions with food and other drugs on the kinetics of the organic nitrates. It is very difficult to correlate the effects of the nitrates to their plasma concentrations; counter-regulation, development of tolerance, and the presence of metabolites could disturb the interpretation of such a relationship. It is at present impossible to predict the pharmacological effects or the efficacy of organic nitrates on the basis of their plasma concentrations.
通过不同给药途径给予人体后,已测定了甘油三硝酸酯(硝酸甘油)、二硝酸异山梨酯以及异山梨醇2 - 单硝酸酯和5 - 单硝酸酯的血浆浓度。在给予这些药物时(为避免静脉输注过程中的损失)以及在其采样和测定过程中,必须采取适当的预防措施。基于血浆浓度的药代动力学计算应谨慎看待,因为这些计算所依据的数据往往非常有限,而且例如硝酸甘油从血浆中极快消失,使得选择合适的动力学模型和进行精确计算变得困难。硝酸甘油在几分钟内就从血浆中消失,且分布容积大、全身清除率高。口服给药后,血浆浓度非常低;舌下或经皮给药时,可获得较高的血浆浓度,这表明口服给药后首过效应明显,但缺乏生物利用度的定量数据。对于二硝酸异山梨酯,尽管全身清除率较高,但低于硝酸甘油;从血浆中消失的速度较慢,不同给药途径后的血浆浓度要高得多。同样,这里也缺乏生物利用度的定量数据。给予二硝酸异山梨酯后,血浆中可检测到高浓度的异山梨醇2 - 单硝酸酯和异山梨醇5 - 单硝酸酯。这些代谢产物具有良好的生物利用度,异山梨醇2 - 单硝酸酯的半衰期约为2.5小时,异山梨醇5 - 单硝酸酯的半衰期约为5小时。关于疾病状态以及与食物和其他药物的相互作用对有机硝酸盐动力学的影响,仅有非常有限的数据。将硝酸盐的效应与其血浆浓度相关联非常困难;反调节、耐受性的发展以及代谢产物的存在可能会干扰这种关系的解释。目前,不可能根据有机硝酸盐的血浆浓度预测其药理作用或疗效。